BLR&D Research Career Scientist Award Application
BLR
基本信息
- 批准号:10451505
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAgeAmericanAnidulafunginAntifungal AgentsAreaArthritisAwardBiologicalBiological AssayBone MarrowCaringCaspofunginCell LineCell WallChemicalsChloroquineChronicChronic DiseaseChronic Obstructive Pulmonary DiseaseClinicalCollaborationsDataDevelopmentDihydrofolate Reductase InhibitorDiseaseDoseDrug ScreeningElderlyEvaluationFemaleGene ExpressionGene Expression ProfilingGeneral PopulationGenesGoalsHIVHIV SeronegativityHIV SeropositivityHealthcareHematological DiseaseHumanImmuneImmune systemImmunocompromised HostImmunosuppressionImmunotherapyIn VitroInfectionInfection preventionInternationalInterruptionKnowledgeLengthLife Cycle StagesLungMalignant NeoplasmsMammalian CellMethodsMicafunginMicrobiologyMicroscopicMidwestern United StatesMissionModelingMorbidity - disease rateMusMycosesOhioOpportunistic InfectionsOutcomePartner in relationshipPatientsPharmaceutical PreparationsPhasePneumocystisPneumocystis InfectionsPneumocystis cariniiPneumocystis carinii PneumoniaPneumoniaPolandPopulationPortugalPreclinical Drug DevelopmentProliferatingPropertyProphylactic treatmentPublicationsRattusReportingResearchRheumatoid ArthritisRiskRodent ModelRoleScientistSeminalSexual ReproductionSocietiesSphingolipidsStressSulfamethoxazoleTherapeuticTimeToxic effectTrimethoprim-sulfamethoxazole drug resistanceUnited StatesUp-RegulationVeteransWithdrawalanalogantimicrobialasexualbasecancer diagnosiscandidate identificationcareercelecoxibchronic inflammatory diseaseclinically relevantcomorbidityefficacy testingexperimental studyfungushigh riskimmunological statusimmunosuppressedinfected vector rodentknockout genemalemetabolic abnormality assessmentmilitary veteranmortalitymouse modelnew therapeutic targetnovel therapeuticspathogenpathogenic funguspolyglucosanpre-clinicalprophylacticresponsescreeningsextargeted treatmenttherapy durationtooltranscriptome sequencingtransmission processtumor necrosis factor-alpha inhibitor
项目摘要
Pneumocystis spp. are obligate fungal pathogens that cause a fatal pneumonia (PCP) in immunocompromised
hosts. Few drugs are effective against PCP and there have been no new therapies for its treatment in decades.
Typically, PCP has been associated with patients infected with HIV, however, the fulminate pneumonia, PCP,
and colonization with Pneumocystis jirovecii (the species infecting humans) are emerging clinical problems in
newly susceptible populations in the general and veterans’ populations including bone marrow recipients;
patients receiving immunotherapy for rheumatoid arthritis and other chronic inflammatory diseases; and cancer
chemo- and immunotherapies. The life cycle of Pneumocystis is suggested to contain both an asexual replication
cycle and a sexual cycle involving mating with subsequent formation of asci containing 8 ascospores (1). During
the previous Merit Review, we showed that echinocandin treatment of rodents infected with P. murina and P.
carinii, which target β-1,3-D-glucan synthesis (BG), depleted the asci which contain BG but large numbers of
non-BG expressing life cycle stages remained in the lungs and were unable to proliferate. We further
demonstrated that anidulafungin and caspofungin could prevent infection in a prophylactic model, suggesting
that formation of asci via the sexual cycle may be required for a productive infection (2). Analysis of gene
expression profiles of P. murina in mice treated with anidulafungin, showed strong upregulation of genes
associated with sexual replication, though the resulting infections were devoid of asci, the product of sexual
reproduction, suggesting that P. murina attempted to undergo sexual replication, but could not due to a lack of
BG. Based on these data, we posited that asci, and thus sexual replication, is required to facilitate progression
through the life cycle leading to a productive infection. We further posited that presence of asci is required for
transmission of Pneumocystis infection. In the present Merit Review, we will explore 2 critical but unanswered
questions that will lead to a deeper knowledge of the life cycle of Pneumocystis, and also suggest potential
vulnerabilities for targeted treatment concomitant with anidulafungin therapy: (1) Is sexual replication required
for completion of the life cycle of Pneumocystis? Tracking of the replication status of P. murina during
prolonged treatment with anidulafungin by global gene analysis, BG content, and microscopic methods will reveal
whether the non-BG expressing forms numbers remain: 1) static over time, 2) increase, or 3) decrease;
suggesting: 1) the lack of BG blocks replication; 2) that an asexual or alternative replication phase permits
survival of the fungi; or 3) the lack of sexual replication results in elimination of the infection. (2) Can sexual
replication rebound after cessation of prolonged anidulafungin treatment? Mice will be treated with
anidulafungin for up to 8 weeks, with 2 cessation time points. Mice in the cessation groups will be tracked for
microscopic, BG content, and gene expression evidence of asci formation and return of the pneumonia while
remaining under immunosuppression. Mice in the treated and cessation groups will be evaluated for their ability
to transmit the infection and the critical number of asci needed for transmission. All studies will be conducted in
male and female mice, recognizing sex as a biological variable. The echinocandins are clinically available in the
United States. Current monotherapy with any echinocandin for PCP is not warranted as withdrawal can result in
return of the pneumonia. The results of the proposed studies will have immediate clinical relevance by
determining the length of time viable Pneumocystis can remain in the lungs with concurrent anidulafungin
treatment, providing a rationale for duration of therapy with eradication as the goal. These experiments will also
identify whether immunosuppressed mice can transmit the infection after withdrawal of anidulafungin and if there
is a critical number of asci needed. Finally, the studies will elaborate the life cycle of Pneumocystis and suggest
new target strategies.
肺孢子虫。引起致命性肺炎(PCP)的专性真菌病原体是否受到免疫抑制
主持人。很少有药物能有效治疗PCP,而且几十年来一直没有新的治疗方法。
通常情况下,PCP与感染艾滋病毒的患者有关,然而,暴发性肺炎、PCP、
和感染人类的肺孢子虫的定植是#年出现的临床问题。
普通人群和退伍军人人群中的新易感人群,包括骨髓接受者;
接受免疫治疗的类风湿性关节炎和其他慢性炎症性疾病的患者;以及癌症
化疗和免疫疗法。肺孢子虫的生命周期被认为包含无性复制
周期和有性周期,包括交配,随后形成含有8个子囊孢子的子囊孢子(1)。在.期间
先前的优点综述表明,棘球菌素治疗感染P.Murina和P.
以β-1,3-D-葡聚糖(BG)合成为靶标的Carinii,耗尽了含有BG但大量
非BG表达的生命周期阶段留在肺内,不能增殖。我们进一步
证明了阿尼度芬净和卡泊芬净可以预防预防模型中的感染,提示
通过性周期形成ASCI可能是生产性感染所必需的(2)。基因分析
阿尼杜拉芬净处理小鼠后,小鼠肺泡巨噬细胞基因表达谱明显上调
与性复制有关,尽管由此产生的感染没有ASCI,这是性复制的产物
繁殖,这表明P.Murina试图进行有性复制,但由于缺乏
BG。根据这些数据,我们假设ASCI,从而性复制,是促进进展所必需的
通过生命周期导致生产性感染。我们进一步假设,ASCI的存在是
肺孢子虫感染的传播。在目前的功绩回顾中,我们将探索两个关键但未得到回答的问题
这些问题将导致对肺孢子虫生命周期的更深层次的了解,并暗示潜在的
靶向治疗的脆弱性伴随着阿尼度芬净治疗:(1)是否需要性复制
为了完成肺孢子虫的生命周期?过程中对P.Murina复制状态的跟踪
通过全球基因分析、血糖含量和显微镜方法,延长阿尼度芬净的治疗时间将揭示
非BG表达形式的数量是否保持:1)随着时间的推移保持不变,2)增加,或3)减少;
这表明:1)缺乏BG阻碍了复制;2)无性或替代复制阶段允许
真菌的存活;或3)缺乏有性复制导致感染的消除。(2)可以性行为
延长的阿尼杜拉芬净治疗停止后复制反弹?小鼠将被用来治疗
阿尼杜拉芬净疗程长达8周,有2个停药时间点。戒毒组中的小鼠将被跟踪
肺炎ASCI形成和复发的显微镜、血糖含量和基因表达证据
仍处于免疫抑制状态。治疗组和戒毒组的小鼠将被评估它们的能力
以传播感染和传播所需的ASCI临界数量。所有研究都将在
雄性和雌性小鼠,认为性是一个生物变量。棘球菌素在临床上可用于
美国。目前对PCP采用任何棘球菌素单一疗法都是不必要的,因为停药可能会导致
肺炎又回来了。拟议的研究结果将在以下方面具有直接的临床意义
同时给予阿尼杜拉芬太尼的肺孢子虫存活时间长短的测定
治疗,为以根除为目标的治疗持续时间提供了理由。这些实验还将
确定免疫抑制的小鼠在停药后是否会传播感染,以及
是所需的关键数量的ASCI。最后,这些研究将阐述肺孢子虫的生命周期,并建议
新的目标战略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Melanie T Cushion其他文献
Melanie T Cushion的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Melanie T Cushion', 18)}}的其他基金
The role of sex in the life cycle and transmission of Pneumocystis
性在肺孢子虫生命周期和传播中的作用
- 批准号:
10350565 - 财政年份:2019
- 资助金额:
-- - 项目类别:
International Workshop on Opportunistic Protists (IWOP-14)
机会性原生生物国际研讨会(IWOP-14)
- 批准号:
9398434 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Directed Culturing of Pneumocystis Using Metatranscriptomics
利用宏转录组学定向培养肺孢子虫
- 批准号:
8664916 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Directed Culturing of Pneumocystis Using Metatranscriptomics
利用宏转录组学定向培养肺孢子虫
- 批准号:
8554433 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Immunopathology of the Pneumocystis Life Cycle Stages
肺孢子虫生命周期阶段的免疫病理学
- 批准号:
8397516 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Immunopathology of the Pneumocystis Life Cycle Stages
肺孢子虫生命周期阶段的免疫病理学
- 批准号:
7929730 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Immunopathology of the Pneumocystis Life Cycle Stages
肺孢子虫生命周期阶段的免疫病理学
- 批准号:
8195572 - 财政年份:2010
- 资助金额:
-- - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Queer and Environmental Melancholia in American Coming-of-age Fiction: Narratives of Loss and Resistance in the Anthropocene
美国成长小说中的酷儿与环境忧郁:人类世的失落与抵抗的叙述
- 批准号:
2883761 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Studentship
The Representations of "Nature" by 19th Century American Women Poets: Perspectives in the Age of "War
19世纪美国女诗人对“自然”的再现:“战争”时代的视角
- 批准号:
22K00434 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Representations of Waste People in the New World: American National Identity in the Age of the Nation-State and Beyond
新世界中废人的表征:民族国家时代及以后的美国民族认同
- 批准号:
22K00491 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
The American Public Broadcasting in the Internet Age: How they adopt the System, Mission, and Regulations during the IT Revolution?
网络时代的美国公共广播:IT革命期间他们如何采用制度、使命和规则?
- 批准号:
20K13715 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Work of Art in the Age of Empathy: Analyzing American and Soviet Culture during the Interwar Period
移情时代的艺术作品:分析两次世界大战期间的美国和苏联文化
- 批准号:
20J40040 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Grant-in-Aid for JSPS Fellows
Latin American Antiracism in a 'Post-Racial' Age
“后种族”时代的拉丁美洲反种族主义
- 批准号:
ES/N012747/1 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Research Grant
The Philosophy of May Massee, an Editor who Brought about the Golden Age of American Picture Books
开启美国图画书黄金时代的编辑梅·马西的哲学
- 批准号:
16K02512 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Spaces of Education: Pedagogical Writing and Social Practice in the Age of American Romanticism
教育空间:美国浪漫主义时代的教学写作与社会实践
- 批准号:
323813051 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Research Grants
Collaborative Research: American Innovations in an Age of Discovery: Teaching Science and Engineering through 3D-printed Historical Reconstructions
合作研究:发现时代的美国创新:通过 3D 打印历史重建教授科学与工程
- 批准号:
1510289 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Continuing Grant
Collaborative Research: American Innovations in an Age of Discovery: Teaching Science and Engineering through 3D-printed Historical Reconstructions
合作研究:发现时代的美国创新:通过 3D 打印历史重建教授科学与工程
- 批准号:
1511155 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Continuing Grant














{{item.name}}会员




